Drug profile · INN
riociguat
ADEMPAS
riociguat (ADEMPAS) is a soluble guanylate cyclase positive allosteric modulator. Associated with Bayer Australia Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — riociguat
- US status
- approved
- Class
- Cardiovascular system (C02)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
riociguat (ADEMPAS) is a soluble guanylate cyclase positive allosteric modulator. Associated with Bayer Australia Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Soluble guanylate cyclase positive allosteric modulator
Primary target: Soluble guanylate cyclase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is riociguat?
riociguat (ADEMPAS) is a soluble guanylate cyclase positive allosteric modulator. Associated with Bayer Australia Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for riociguat?
ADEMPAS is a marketed brand name for riociguat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of riociguat?
riociguat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.